Stock Price Quote

NOVELIX PHARMACEUTICALS LTD.

NSE : NABSE : 536565ISIN CODE : INE314I01036Industry : TradingHouse : Private
BSE54.301.41 (+2.67 %)
PREV CLOSE ( ) 52.89
OPEN PRICE ( ) 54.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 14111
TODAY'S LOW / HIGH ( )52.52 55.45
52 WK LOW / HIGH ( ) 24.1570.16
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1994
Management Info
- Chairman - Managing Director
Registered Office

Address Amrutha Estates, 6th Floor,H. No. 3-6-237/610, Lingapur La Builders,Himayath Nagar,
Hyderabad,
Telangana-500029

Phone 8977631044

Email novelixpharmaceuticals@gmail.com

Website www.trimurthidrugs.com

Registrars Details
Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
Listing : BSE

NEWS

23Oct Allotment of Convertible warrants
Inter alia, approved the allotment of 16,61,000 equity shares of the fac..
23Oct Allotment of Equity Shares
Inter alia, approved the allotment of 16,61,000 equity shares of the fac..
17Oct Novelix Pharmaceuticals signs technolo
Novelix Pharmaceuticals has signed a Technology Transfer agreement with..
17Oct Novelix Pharmaceuticals touches roof o
Novelix Pharmaceuticals is currently trading at upper limit of Rs. 44.15..
21Jun Novelix Pharmaceuticals informs about
Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Re..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit5.319999999999990.829999999999966
Gross Profit 7.17999999999999 1.21999999999997
Operating Profit 7.319999999999991.59999999999997
Net Sales 363.59307.18

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

The Yamuna Syndicate (BSE)
peergroup  27199.00 (0.34%)
M.Cap ( in Cr)836.00
Riddhi Siddhi Gluco (BSE)
peergroup  485.05 (13.07%)
M.Cap ( in Cr)345.83
Ausom Enterprise (BSE)
peergroup  153.50 (19.97%)
M.Cap ( in Cr)209.12
Nanta Tech (BSE)
peergroup  288.30 (9.41%)
M.Cap ( in Cr)147.90
Omnitex Industries (BSE)
peergroup  544.70 (4.44%)
M.Cap ( in Cr)229.00

Shareholding Pattern

PROMOTERS 53.33%
NON-INSTITUTION 46.67%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Novelix Pharmaceuticals Ltd.

Novelix Pharmaceuticals Ltd. was incorporated in the year 1994. Its today's share price is 54.3. Its current market capitalisation stands at Rs 93.48 Cr. In the latest quarter, company has reported Gross Sales of Rs. 307.18 Cr and Total Income of Rs.307.34 Cr. The company's management includes Sridevi Belide, Nishita Kalantri, Mayuri Baidya, Gattu Gnana Prakash, Lakshman Samala, Jivamohan Divakar Valluri, Janardhan Das Kabra, Venkateshwarlu Pulluru.

It is listed on the BSE with a BSE Code of 536565 , NSE with an NSE Symbol of and ISIN of INE314I01036. It's Registered office is at Amrutha Estates, 6th Floor,H. No. 3-6-237/610, Lingapur La Builders,Himayath NagarHyderabad-500029, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are CVS Balachandra Rao & Co, K Venkateswara Rao & Associates, P Murali & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.